Aurora Cannabis Extends Australian Reach Via Leafio Partnership Covering 4,000+ Pharmacies

Aurora Cannabis Inc.’s (NASDAQ: ACB) (TSX: ACB) wholly owned subsidiary MedReleaf Australia has partnered with Leafio, the wholesale distribution arm of Montu Australia.

Under the deal, Leafio agreed to serve as a wholesaler for Aurora’s portfolio of medical cannabis products sold under the MedReleaf, CraftPlant, Aurora, Whistler Cannabis Co. and IndiMed brands, the Canadian cannabis giant announced on Tuesday.

The strategic distribution partnership aims to give patients wider access to trusted, safe and effective medical cannabis across Australia through Leafio’s nationwide supply chain, which services more than 4,000 pharmacies.

Stanley Sack, interim managing director of MedReleaf Australia, praised the new collaboration.

“Our TGA-GMP certified products combined with Leafio’s extensive sector knowledge and focus on clinician education make us ideal partners as we continue to grow our leadership in this important market,” Sack said.

Aurora’s total revenue for the second quarter of 2026 increased 11% year-over-year, due to 15% growth in Aurora’s global medical cannabis business and 34% growth in its plant propagation business.

The increase in medical cannabis net revenue of $9.2 million was primarily due to higher sales to Australia, Germany, Poland, and the UK, as well as increased revenue in Canada to insurance-covered and self-paying patients, the company said in November.

That said, Aurora recently ramped up its presence in Europe as well, by announcing a five-year investment to enhance operations at its EU-GMP manufacturing facility in Leuna, Germany.

ACB Price Action

Aurora’s shares traded 0.2207% higher at $4.54 per share at the time of writing on Tuesday.